Pharmacological treatment

Clonazepam add‐on therapy for refractory epilepsy in adults and children

Abstract Background Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug‐refractory epilepsy. People with drug‐refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. Objectives To assess the efficacy and tolerability of clonazepam when used as an add‐on therapy foradults and children with […]

Share

Rufinamide add-on therapy for refractory epilepsy

Abstract Background Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often […]

Share

Losigamone add-on therapy for partial epilepsy

Abstract Background Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated […]

Share

Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children

Abstract Background Tonic-clonic convulsions and convulsive status epilepticus (currently defined as a tonic-clonic convulsion lasting at least 30 minutes) are medical emergencies and require urgent and appropriate anticonvulsant treatment. International consensus is that an anticonvulsant drug should be administered for any tonic-clonic convulsion that has been continuing for at least five minutes. Benzodiazepines (diazepam, lorazepam, […]

Share

Eslicarbazepine acetate add-on for drug-resistant partial epilepsy

Abstract Background This is an updated version of the Cochrane Review published in the Cochrane Library 2011, Issue 12. The majority of people with epilepsy have a good prognosis, but up to 30% of people continue to have seizures despite several regimens of antiepileptic drugs. In this review, we summarized the current evidence regarding eslicarbazepine […]

Share

Intravenous immunoglobulins for epilepsy

Abstract Background Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may […]

Share

Felbamate as an add-on therapy for refractory epilepsy

Abstract Background This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 7, 2014) on ‘Felbamate as an add-on therapy for refractory epilepsy’. Epilepsy is a chronic and disabling neurologic disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that […]

Share

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data

Abstract Background Epilepsy is a common neurological condition with a worldwide prevalence of around 1%. Approximately 60% to 70% of people with epilepsy will achieve a longer-term remission from seizures, and most achieve that remission shortly after starting antiepileptic drug treatment. Most people with epilepsy are treated with a single antiepileptic drug (monotherapy) and current […]

Share

Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis

Abstract Background Viral encephalitis is characterised by diverse clinical and epidemiological features. Seizures are an important clinical manifestation and are associated with increased mortality and morbidity. Patients may have seizures during the acute illness or they may develop after recovery. There are no recommendations regarding the use of antiepileptic drugs for the primary or secondary […]

Share

Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy

Abstract Background This is an updated version of the original Cochrane review published in 2015, Issue 10. Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for which stiripentol (STP) has been recently licensed as add-on therapy. Objectives To evaluate the efficacy and tolerability of STP […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share